Saros Therapeutics is developing an innate immune activation technology for oncology. While immunotherapy has revolutionized cancer care, it still benefits only a small fraction of patients. Saros' lead program targets the STING pathway and was engineered to overcome the problems with prior STING agonists. We have early partnering opportunities for assets targeting both the STING and TLR pathways, with significant data supporting efficacy, safety and mechanism of action. The founding team brings deep experience from large pharmaceutical companies, small biotechs, and a founding academic team with prior biotech startup experiences. Saros is seeking funding to bring the lead program into and through a phase 1 clinical readout while developing the other assets in its pipeline for partnerships.
Speaker
